Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era

IMPORTANCE: In 2015, first-line programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICI) were Food and Drug Administration (FDA)-approved and National Comprehensive Cancer Network (NCCN)-recommended for patients with stage IV melanoma. Few studies have assessed the overall survival (OS) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamba, Nayan, Ott, Patrick A., Iorgulescu, J. Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412220/
https://www.ncbi.nlm.nih.gov/pubmed/36006646
http://dx.doi.org/10.1001/jamanetworkopen.2022.25459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412220/
https://www.ncbi.nlm.nih.gov/pubmed/36006646
http://dx.doi.org/10.1001/jamanetworkopen.2022.25459

Ejemplares similares